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Background: Endothelial nitric oxide synthase (eNOS)-uncoupling links obesity-associated insulin resistance and
type-II diabetes to the increased incidence of cardiovascular disease. Studies have indicated that increased arginase
is involved in eNOS-uncoupling through competing with the substrate L-arginine. Given that arginase-II (Arg-II)
exerts some of its biological functions through crosstalk with signal transduction pathways, and that p38
mitogen-activated protein kinase (p38mapk) is involved in eNOS-uncoupling, we investigated here whether
p38mapk is involved in Arg-II-mediated eNOS-uncoupling in a high fat diet (HFD)-induced obesity mouse model.
Methods: Obesity was induced in wild type (WT) and Arg-II-deficient (Arg-II-/-) mice on C57BL/6 J background by
high-fat diet (HFD, 55% fat) for 14 weeks starting from age of 7 weeks. The entire aortas were isolated and subjected
to 1) immunoblotting analysis of the protein level of eNOS, Arg-II and p38mapk activation; 2) arginase activity assay;
3) endothelium-dependent and independent vasomotor responses; 4) en face staining of superoxide anion and NO
production with Dihydroethidium and 4,5-Diaminofluorescein Diacetate, respectively, to assess eNOS-uncoupling. To
evaluate the role of p38mapk, isolated aortas were treated with p38mapk inhibitor SB203580 (10 μmol/L, 1 h) prior to
the analysis. In addition, the role of p38mapk in Arg-II-induced eNOS-uncoupling was investigated in cultured human
endothelial cells overexpressing Arg-II in the absence or presence of shRNA against p38mapk.
Results: HFD enhanced Arg-II expression/activity and p38mapk activity, which was associated with eNOS-uncoupling
as revealed by decreased NO and enhanced L-NAME-inhibitable superoxide in aortas of WT obese mice. In accordance,
WT obese mice revealed decreased endothelium-dependent relaxations to acetylcholine despite of higher eNOS
protein level, whereas Arg-II-/- obese mice were protected from HFD-induced eNOS-uncoupling and endothelial
dysfunction, which was associated with reduced p38mapk activation in aortas of the Arg-II-/- obese mice. Moreover,
overexpression of Arg-II in human endothelial cells caused eNOS-uncoupling and augmented p38mapk activation. The
Arg-II-induced eNOS-uncoupling was prevented by silencing p38mapk. Furthermore, pharmacological inhibition of
p38mapk recouples eNOS in isolated aortas from WT obese mice.
Conclusions: Taking together, we demonstrate here for the first time that Arg-II causes eNOS-uncoupling through
activation of p38 mapk in HFD-induced obesity.
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Obesity and obesity-associated metabolic disorders are
important risk factors of ischemic coronary heart disease
[1]. Clinical and experimental studies demonstrate that
obesity is associated with decreased endothelial nitric
oxide (NO) bioavailability [2,3], a hallmark of athero-
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unless otherwise stated.NO, produced from the substrate L-arginine by endo-
thelial NO synthase (eNOS), exerts vascular protective
effects through vasodilatation, inhibition of thrombosis,
smooth muscle cell proliferation and vascular inflamma-
tion [5]. eNOS-uncoupling in which the enzyme gene-
rates superoxide anion instead of NO has been shown to
be an important mechanism of endothelial dysfunction
under numerous physiological and pathological con-
ditions including aging, atherosclerosis, and obesity [6].
The mechanisms of eNOS-uncoupling are multifactorial
and have not been fully elucidated [7]. Recent studiesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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hydrolase, arginase, including type-I and type-II arginase
(Arg-I and Arg-II), is involved in eNOS-uncoupling in
vascular diseases [8-10].
The endothelial cells express both Arg-I and Arg-II
and share similar functions with respect to the negative
regulation of eNOS functions [9]. Compelling evidence
implicates that Arg-II plays a dominant role in eNOS-
uncoupling in human and mouse blood vessels [10,11].
Our recent studies demonstrate that genetic ablation of
Arg-II in mice reduces atherosclerosis on the ApoE-/-
background, improves glucose homeostasis and insulin
sensitivity in mice fed a high fat diet (HFD), which is at
least partly attributable to dampening of macrophage in-
flammatory responses [12]. Moreover, genetic ablation of
Arg-II slows down endothelial senescence and protects
mice from age-associated endothelial inflammatory re-
sponses through inhibition of eNOS-uncoupling [10],
implying a causative role of Arg-II in eNOS-uncoupling
and endothelial dysfunction in aging. Although eNOS-
uncoupling has been described in obesity [13], it is
however not known whether Arg-II plays a role in this
context in obesity.
Evidence has been presented that p38mapk is an im-
portant signaling pathway sensing cellular stress and is
involved in pathogenesis of cardiovascular diseases and
eNOS-uncoupling [14,15]. Mammalian p38mapk has
four isoforms, α, β, δ, γ, which are expressed to different
extent in specific cells and tissues, and function as
sensors to various stressors, including oxidative stress,
inflammatory stimuli, oncogenes [14,16]. Of the four
enzyme isoforms, p38α is the best recognized isoenzyme
of cardiovascular importance [14]. Pharmacological inhib-
ition of p38mapk has been shown to reduce atherogenesis
and improve plaque stability in animal models [17,18] and
protects against ischemic myocardial injury [14,19], which
can be partly attributed to inhibition of inflammatory re-
sponses and foam cell formation [20,21]. In endothelial
cells, p38mapk has been reported to mediate apoptosis
and senescence [22,23]. Inhibition of p38mapk in animals
and humans is able to improve endothelium-mediated
vascular relaxations [15,20], and p38mapk has been shown
to be increased in the arteries of obesity animal models
[24], suggesting a role of p38mapk in endothelial dysfunc-
tion in obesity.
Previous studies suggest that p38mapk acts upstream
of Arg-II, which mediates endothelial dysfunction of
corpus cavernosum in angiotensin II-induced hyperten-
sion mouse model [25]. However, the effects of p38mapk
and Arg-II on endothelial dysfunction in obesity and
insulin resistance are not known. The aim of our cur-
rent study is to investigate whether Arg-II plays a role
in eNOS-uncoupling in obesity, and whether p38mapk
is involved.Materials and methods
Materials
Reagents were purchased or obtained from the follo-
wing sources: rabbit antibody against Arg-II was from
Santa Cruz Technology Inc. (Nunningen, Switzerland);
mouse antibodies against eNOS and p38mapk, rabbit
antibodies against phospho-p38mapk (Thr180/Tyr182)
and phospho-Ser1177-eNOS were purchased from Cell
Signaling (Allschwil, Switzerland); mouse antibody against
tubulin was from Sigma (Buchs, Switzerland). IRDye 800-
conjugated affinity purified goat anti-rabbit IgG F(c)
was purchased from BioConcept (Alschwil, Switzerland),
Alexa fluor 680-conjugated goat anti–mouse IgG (H + L)
was from Invitrogen (Lucerne, Switzerland). Dihydro-
ethidium (DHE) was from Molecular Probes/Invitrogen
(Lucerne, Switzerland), and the membrane-permeable 4,5-
diaminofluoresceine diacetate (DAF-2DA) was from VWR
international SA (Dietikon, Switzerland). L-norepinephrine
bitartrate, acetylcholine (ACh), sodium nitroprusside (SNP)
and SB203580 were purchased from Calbiochem. All cell
culture media and materials were purchased from Gibco
BRL (Lucerne, Switzerland).
Animals
The Arg-II-/- mice were kindly provided by Dr. William
O’Brien [26] and backcrossed to C57BL/6 J for more
than ten generations [12]. Genotyping was performed by
polymerase chain reaction (PCR) as previously described
[26]. The WT and Arg-II-/- offsprings from hetero/hetero
cross were interbred to obtain WT and Arg-II-/- mice, res-
pectively, for experiments. Starting at the age of 7 weeks,
the male WT and Arg-II-/- mice were given free access
during 14 weeks to either a normal chow (NC; energy
content: 10.6% fat, 27.6% protein, and 57% carbohydrate,
fiber 4.8%; Provimi Kliba NAFAG 3436; Kaiseraugst,
Switzerland) or a high fat diet (HFD, energy content:
55% fat, 21% protein, and 24% carbohydrate; Harlan
Teklad TD 93075; Horst, Netherlands). Animals were
sacrificed after 14 weeks of HFD. The entire aortas from
the heart to the iliac bifurcation were removed, placed into
cold (4°C) Krebs bicarbonate solution, dissected free from
fat and adhering perivascular tissue. The isolated aortic
rings were used either for vasomotor response measure-
ment in an organ chamber setup (see below), en face
staining of Superoxide anion and NO (see below), or
snap-frozen in liquid nitrogen and kept at -80°C until
used for immunoblotting analysis and arginase activity
assay. Animal handling and experimentation were ap-
proved by the Service de la sécurité alimentaire et des af-
faires vétérinaires, Etat de Fribourg.
Generation of recombinant adenovirus (rAd)
Generation of rAd expressing shRNA targeting hu-
man p38mapkα driven by the U6 promoter (rAd/U6-
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nology (Invitrogen Life Technologies) according to ma-
nufacturer’s instructions. The targeting sequence for
hp38α-shRNA is indicated in boldface below (only the
sense strand is shown):
5′-CACCGTTACGTGTGGCAGTGAAGAACGAAT
TCTTCACTGCCACACGTAAC-3′.
rAd/U6-LacZshRNA, rAd/CMV empty vector and rAd/
CMV-Arg-II were generated as previously described [10].
Endothelial cell culture and adenoviral transduction of
the cells
Cultivation and transduction of Human umbilical vein
endothelial cells (HUVECs) were performed as previ-
ously described [11]. Cells were transduced with the rAd
at titers of ~200 multiplicities of infection and then
cultured in complete medium for 2 to 4 days before
experiments.
Detection of NO and superoxide level in cultured
endothelial cells and in intact mouse aortas
NO and superoxide levels in cultured endothelial cells as
well as in intact mouse aortas were assessed by staining
the cells or aortas en face with fluorescent dyes DAF-
2DA and DHE, respectively, as described previously [27].
Briefly, Z-scanning was done for each sample. After the
signal on the top (endothelial layer on the lumen border)
of the sample was observed, the images were collected.
Three consecutive images per field, acquired through
the full thickness of endothelial signal, were recorded for
analysis. At least 3 different fields per sample were eval-
uated. The images from DAF-2DA and DAPI staining
were quantified with Image J software and results are
presented as the ratio of DAF-2DA and DAPI or ratio of
DHE and DAPI positive nucleus.
Measurement of arginase activity
Arginase activity in the aortic tissue lysates was mea-
sured by colorimetric determination of urea formed
from L-arginine in an in vitro activity assay as previ-
ously described [11].
Immunoblotting analysis
Preparation of mouse aortic tissue and endothelium
cell extract, SDS-PAGE, transfer of SDS gels to an
Immobilon-P membrane (Millipore) were performed
as previously described [12]. The resultant membrane
was incubated overnight with the corresponding pri-
mary antibody (1:2500 for eNOS, 1:500 for phospho-
Ser1177-eNOS, 1:200 for arginase-II and 1:1000 for
p38mapk and phospho-Thr180/Tyr182-p38mapk) at
4°C with gentle agitation after blocking with 5% skimmedmilk. The protein was decorated with a corresponding
anti-mouse (Alexa fluor 680 conjugated) or anti-rabbit
(IRDye 800 conjugated) and detected by Odyssey Infrared
Imaging System (LI-COR Biosciences). Quantification of
the signals was performed using the Odyssey Application
Software 1.2.
Endothelium-dependent and independent responses
Endothelium-dependent and independent relaxations were
studied as previously described [11]. Briefly, the descending
thoracic aortas with intact endothelium cleaned of peri-
vascular tissues were cut into rings (3 mm in length)
and then suspended in a Multi-Myograph System (Model
610 M, Danish Myo Technology A/S, Denmark). The
endothelium-dependent relaxations in response to acetyl-
choline (1 nmol/L to 10 μmol/L) and endothelium-
independent relaxations in response to the NO donor
sodium nitroprusside (SNP, 0.1 nmol/L to 1 μmol/L) were
then performed in aortic rings precontracted with norepin-
ephrine (0.1 to 0.3 μmol/L) to match the precontraction.
Statistics
Data are given as mean ± SEM. In all experiments, n in-
dicates the number of individual animals used or of indi-
vidual experiments when conducted with cultured cells.
Statistical analysis was performed with unpaired Student
t test or ANOVA with Dunnett or Bonferroni post-test.
Differences in mean values were considered significant
at p < 0.05.
Results
Augmented Arg-II expression/activity and p38mapk
activation in the aortas of obese mice
To study the role of Arg-II in eNOS dysfunction in obe-
sity, eNOS levels and Arg-II expression/activity in the
aortas of mice fed HFD were analyzed. Our previous stu-
dy showed that Arg-II-/- mice are protected from low
grade systemic inflammation, insulin resistance, and glu-
cose intolerance, despite comparable body weight under
HFD feeding [12]. In this study, we further analyzed vas-
cular endothelial function in the obesity mouse model
and showed that the protein level of eNOS in the aortas
of obese mice fed HFD was significantly higher than that
of lean mice fed NC, while the activating eNOS-S1177
phosphorylation level was comparable between the two
groups, which results in a decreased eNOS-S1177/total
eNOS ratio (Figure 1A). The results implicate a de-
creased activation of eNOS in HFD-induced obesity.
In addition, a significantly higher Arg-II expression and
enzymatic activity, and a small but significantly aug-
mented p38mapk activation in the aortas were also ob-
served in the obese mice as compared to the lean mice
(Figure 1B), while Arg-I was below the detectable limit.
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Figure 1 HFD feeding enhances eNOS, Arg-II expression/activity, and p38mapk activation in mouse aortas. (A) Immunoblotting analysis
of eNOS total protein and eNOS-S1177 (p-eNOS) levels (n = 5). (B) Immunoblotting analysis of Arg-II (Arg-I not detectable, tubulin served as
loading control), p38mapk activation, i.e., Thr180/Tyr182-phosphorylated p38mapk (p-p38mapk) and total p38mapk in the aortas of WT mice fed
NC or HFD (n = 5), and arginase activity assay (n = 7-9). *p < 0.05 vs NC. In case of analyzing total protein levels such as Arg-II and eNOS, the ratio
of Arg-II/tubulin or eNOS/tubulin in NC group serves as reference. The levels of eNOS and Arg-II expression in HFD group are calculated as fold
changes to those of the NC group.
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activation play important roles in endothelial dysfunc-
tion in obesity.eNOS-uncoupling in obesity
Next we examined whether enhanced Arg-II contrib-
utes to eNOS dysfunction in obesity. The endothelium-
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Figure 2 Arg-II gene deficiency prevents HFD-induced impairment of endothelium-dependent relaxation. (A) Endothelium-dependent
relaxations in response to acetylcholine (ACh) were significantly impaired by HFD feeding in WT mice ( ) and preserved in Arg-II-/- mice ( ).
Arg-II deficiency had no significant effects in mice fed NC. (B) Arg-II deficiency does not affect endothelium-independent relaxations in response
to the NO donor sodium nitroprusside (SNP) in animals fed HFD. n = 6, **p < 0.01 between WT HFD and Arg-II-/- HFD groups.
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were significantly impaired in WT obese mice fed HFD
(Figure 2A). Although Arg-II deficiency did not sig-
nificantly affect HFD-induced weight gain [12], it pre-
served the endothelium-dependent relaxations to ACh
(Figure 2A), whereas the endothelium-independent re-
laxations in response to the NO donor sodium nitro-
prusside (SNP) under HFD feeding were not affected
(Figure 2B). It is to note that Arg-II deficiency had
no significant effects on endothelial function in lean0
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Figure 3 eNOS-uncoupling in obesity. Confocal microscopic en face det
followed by counterstaining with DAPI of aortas. Aortas of WT mice fed NC
(1 mmol/L) for 1 hour followed by acetylcholine (ACh) stimulation (1 μmol/L,
vs NC; †††p < 0.005 vs HFD group. Scale bar = 0.1 mm.mice fed NC (Figure 2A). The results demonstrate im-
pairment of endothelial function not smooth muscle re-
laxation in obesity involving Arg-II. In accordance with
this result, confocal fluorescence microscopy revealed a
decrease in NO (DAF-2DA staining) and an increase in
L-NAME-sensitive superoxide generation (DHE stain-
ing) in the aortic endothelial layer of WT mice fed HFD
as compared to that of the WT mice fed NC (Figure 3),
suggesting a role of Arg-II in eNOS-uncoupling in
obesity.0
.5
.0
.5
***
NC HFD HFD
L-NAME
0
5
10
15
20
25
DHE (n=5)DAF-2DA (n=5)
***
R
el
at
iv
e 
In
te
ns
ity
 
(F
old
 ch
an
ge
)
NC HFD HFD
L-NAME
ection of NO and O2
- by DAF-2DA and DHE staining, respectively,
or HFD were treated with or without the eNOS inhibitor L-NAME
10 minutes) and then DAF-2DA and DHE staining. n = 5; ***p < 0.005
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p38mapk
To study the role of p38mapk in Arg-II-mediated eNOS-
uncoupling in obesity, we examined p38mapk activation
in the aortas of the obese mice. As shown in Figure 4, acti-
vation of p38mapk as measured by phosphorylation levels
of p38mapk at Thr180/Tyr182, which was detected in the
aortas of WT mice fed HFD (Figure 1), was significantly
decreased when Arg-II gene was deficient, implicating an
interaction between Arg-II and p38mapk. To further dem-
onstrate the role of p38mapk in Arg-II-mediated eNOS-
uncoupling in obesity, aortas of WT mice fed HFD were
treated with the p38mapk inhibitor SB203580 (10 μmol/L,
1 hour). The results showed that under the stimulation
with ACh (1 μmol/L, 10 minutes), levels of NO produc-
tion (DAF-2DA staining) in the intact endothelial layer of
the aortas from WT mice fed HFD were significantly en-
hanced by the p38mapk inhibitor SB203580 (Figure 5).
Importantly, NO production in Arg-II-/- mice under HFD
feeding was significantly higher than that in WT mice
under HFD feeding, but comparable to the levels in the
obese WT mice treated with SB203580. This preserved
endothelial NO production in Arg-II-/- mice fed HFD
could not be further enhanced by the p38mapk inhibitor
SB203580 (Figure 5), Moreover, the levels of superoxide
generation (DHE staining) in the WT mice fed HFD were
higher than Arg-II-/-mice, and this enhanced superoxide
generation in obese WT mice was abolished by thep38
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p38mapk (p-p38mapk) and total p38mapk in aortas of WT and Arg-II-/- micp38mapk inhibitor to the levels as in the Arg-II-/- mice
(Figure 5). The results suggest a common mechanism of
endothelial dysfunction mediated by Arg-II and p38mapk
in obesity. The fact that the higher endothelial NO pro-
duction and lower superoxide generation in the Arg-II-/-
mouse aortas could not be further affected by SB203580,
demonstrates that Arg-II plays a causative role in eNOS-
uncoupling in obesity through activation of p38mapk.
Moreover, experiments in cultured human endothelial
cells showed that overexpression of Arg-II gene led to
elevated p38mapk activation (Figure 6A), caused eNOS-
uncoupling as revealed by enhanced superoxide gen-
eration (DHE staining) and reduced NO production
(DAF-2DA staining), which was recoupled by silencing
p38α, the major isoform of the enzyme in endothelial cells
(Figure 6B). The results further strengthen the above con-
clusion that Arg-II causes eNOS-uncoupling involving
p38mapk.
Discussion
Endothelial dysfunction occurs in obesity and diabetes
mellitus including type-I and type-II diabetes and is
viewed as one of the most important mechanisms linking
to diabetic cardiovascular complications [28]. Although
multiple mechanisms underlying endothelial dysfunction
in obesity and diabetes are demonstrated [29], functional
defect of eNOS such as eNOS-uncoupling rather than
decreased eNOS gene expression seems to be the majorArg-II-/-
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Figure 5 Arg-II gene deficiency and inhibition of p38mapk prevent eNOS-uncoupling in obesity. Confocal microscopic en face detection
of NO with DAF-2DA and superoxide with DHE followed by counterstaining with DAPI in intact mouse aortas. Aortas from WT and Arg-II-/- mice
fed HFD were cleaned of perivascular tissues, cut into two parts and subjected to treatment with either DMSO as control (Con) or SB203580
(SB, 10 μmol/L) for 1 hour followed by treatment with acetylcholine (ACh, 1 μmol/L) for 10 minutes before DAF-2DA and DHE staining. n = 5,
**p < 0.01 and ***p < 0.005 vs WT/Con group. Scale bar = 0.1 mm.
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betes [13]. In line with this study, our present study dem-
onstrates that despite augmented eNOS expression in the
aortas of the obese WT mice (Figure 1), the endothelium-
dependent relaxation (not the endothelium-independent
relaxation) is decreased as compared to the lean mice fed
NC (Figure 2), suggesting dysfunctional eNOS or uncoup-
ling of eNOS in obesity. This conclusion is confirmed
by the fact that in the obese WT mice, the increased
superoxide generation is abolished by the eNOS inhibitor
L-NAME (Figure 3). The enhanced eNOS expression
in obesity is not clear and might reflect a compensa-
tory mechanism to counteract oxidative stress under
this condition.
Obesity is associated with systemic and vascular in-
sulin resistance [1]. In the vascular endothelial cells, in-
sulin is able to enhance eNOS activity through protein
kinase B, PKB/Akt, which phosphorylates and activates
eNOS at serine-1177 [30,31]. Defects of insulin signaling
in obesity therefore result in insulin resistance, glucose
intolerance, and decreased vascular endothelial func-
tion [31]. Although our present study shows compar-
able eNOS-S1177 levels between lean and obese mice,we could demonstrate a decreased eNOS-S1177/eNOS ra-
tio resulting from enhanced eNOS total protein levels in
obesity (Figure 1), which implicates vascular insulin resis-
tance in obesity. This mechanism, in addition to eNOS-
uncoupling, must be involved in endothelial dysfunction
in our mouse model.
In the present study, we further demonstrate that
obesity-associated eNOS-uncoupling is due to enhanced
Arg-II expression and activity. First, Arg-II expression
and activity is augmented in the aortas of obese mice fed
HFD (Figure 1); Second, genetic ablation of Arg-II fully
preserved the endothelium-dependent relaxation in HFD-
induced obesity (Figure 2). This protective effect of Arg-II
gene deficiency on endothelium-dependent relaxation is
attributable to recoupling of eNOS function, since HFD
induced eNOS-uncoupling in WT mice as evidenced
by decreased NO production and increased L-NAME-
sensitive superoxide production in the aortic endothe-
lial cells of the WT obese mice (Figure 3), while the aortic
endothelial cells of Arg-II-/- obese mice revealed increased
NO and decreased superoxide production (Figure 5).
These findings are in agreement with our recent studies
demonstrating eNOS-uncoupling induced by Arg-II in
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Figure 6 p38mapk is involved in Arg-II-induced eNOS-uncoupling. (A) In cultured HUVECs, overexpressing Arg-II gene led to elevated
p38mapk activation as measured by the Thr180/Tyr182 phosphorylated p38mapk (p-p38mapk). n = 6, **p < 0.01 vs Con group. (B) HUVECs were
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http://www.cardiab.com/content/13/1/113aging animal models [10]. We have now extended this
function of Arg-II to the obesity-associated type-II dia-
betes model. The role of Arg-II in decreasing eNOS func-
tion has also been reported by other studies showing that
Arg-II activity and expression are enhanced in human dia-
betic corpus cavernosum, and inhibition of the enzyme
enhances NO-dependent relaxations of corpus caverno-
sum smooth muscle in vitro [25,32,33].
Accumulating evidence indicates that p38mapk is in-
volved in endothelial dysfunction and senescence [23,25].
Studies demonstrate that p38mapk is activated in the aor-
tas of angiotensin-II-induced hypertension and in obesity
[24,34]. In line with these studies, we also show signifi-
cantly augmented p38mapk activation in the mouse aortas
of HFD-induced obesity (Figure 1). Activation of p38mapk
involves multiple mechanisms which are not fully un-
derstood, yet [14]. Hyperglycemia has been implicated in
activation of p38mapk in various types of cells including
endothelial cells, cardiomyoblasts, and dendritic cells
[35-37]. This effect of glucose on p38mapk activation
in endothelial cells is concentration- and time-dependent
[37,38]. In our obesity mouse model, increase in fasting
plasma glucose concentration, glucose intolerance, andinsulin intolerance were demonstrated [12]. Thus, hyper-
glycemia in our obesity mouse model could contribute to
p38mapk activation in the vasculature. Besides the role of
p38mapk in endothelial dysfunction, it has also been
shown that p38mapk activation is the initial signaling
event in the regulation of scavenger receptor expression
by high glucose in human dendritic cells, that is required
for subsequent activation of NF-κΒ [36]. These studies
support the current concept that targeting p38mapk may
affect functions of various cell types, leading to beneficial
therapeutic effects in treatment of cardiovascular disease
or dysfunctions associated with risk factors [14]. Indeed,
the results from our present study demonstrate that phar-
macological inhibition of p38mapk improves endothelial
function by inhibition of eNOS-uncoupling in obesity
(Figure 5).
The relationship of p38mapk and Arg-II has been re-
ported in the literature. Inhibition of p38mapk has been
shown to reduce arginase activity and Arg-II expression
and improve corpus cavernosum tissue relaxation in these
animal models [25]. These results indicate that p38mapk
is the upstream signal that enhances Arg-II expression.
In our current study, we provide for the first time the
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effector of Arg-II and mediates Arg-II-induced eNOS-
uncoupling in cultured cells as well as in the obesity
mouse model. This conclusion is supported by the follow-
ing evidences. Firstly, overexpression of Arg-II in cultured
human endothelial cells causes eNOS-uncoupling, which
is prevented by silencing p38mapk (Figure 6); secondly,
p38mapk activation is significantly reduced in the aortas
of obese Arg-II-/- mice as compared to the control WT lit-
termates fed HFD (Figure 4); finally, treatment of the
intact aortas with p38mapk inhibitor recouples eNOS
function, i.e., causes inhibition of superoxide generation
and enhances NO production in obese WT mice without
any further effects on NO or superoxide level in obese
Arg-II-/- mice (Figure 5). It remains to be investigated how
Arg-II activates p38mapk.
In conclusion, our study demonstrates that Arg-II causes
eNOS-uncoupling through activation of p38mapk pathway
in HFD-induced obesity. Targeting vascular Arg-II and/or
p38mapk may represent a novel therapeutic approach for
treatment of vascular diseases associated with insulin re-
sistance and type-II diabetes associated with obesity.
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